Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA2 | Q15349 | 14/20 | 0.53 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19252943 | 1.00 | RPS6KA2 (0.53) | RPS6KA2RPS6KA3HRH3CYP3A4CYP2D6 | |
| SCHEMBL31300701 | 0.84 | RPS6KA2 (0.59) | RPS6KA2RPS6KA3HRH3CYP3A4CYP2D6 | |
| SCHEMBL1979881 | 0.84 | RPS6KA2 (0.59) | RPS6KA2RPS6KA3HRH3CYP3A4CYP2D6 | |
| SCHEMBL4038900 | 0.83 | RPS6KA2 (0.52) | RPS6KA2RPS6KA3HRH3CYP3A4CYP2D6 | |
| SCHEMBL4040510 | 0.83 | RPS6KA2 (0.53) | RPS6KA2RPS6KA3HRH3CYP3A4CYP2D6 | |
| SCHEMBL4038902 | 0.83 | RPS6KA2 (0.52) | RPS6KA2RPS6KA3HRH3CYP3A4CYP2D6 | |
| SCHEMBL4040515 | 0.83 | RPS6KA2 (0.53) | RPS6KA2RPS6KA3HRH3CYP3A4CYP2D6 | |
| SCHEMBL3084066 | 0.83 | RPS6KA2 (0.62) | RPS6KA2RPS6KA3MAPKAPK2 | |
| SCHEMBL1979365 | 0.80 | RPS6KA2 (0.62) | RPS6KA2RPS6KA3MAPKAPK2 | |
| SCHEMBL4046631 | 0.80 | RPS6KA2 (0.50) | RPS6KA2RPS6KA3HRH3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113620950-A | Carboxamide derivatives useful as RSK inhibitors | 凤凰分子设计公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-109071542-B | Carboxamide derivatives useful as RSK inhibitors | 凤凰分子设计公司 | 2021-07-20 | — | — | CN | disclosed |
| EP-3848373-A1 | N-(1-((HETEROCYCLYL)METHYL)-1H-PYRAZOL-4-YL)-6-OXO-6,7,8,9- TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[L,2-A]PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS P90 RIBOSOMAL S6 KINASE (RSK) INHIBITORS FOR TREATING CANCER | Phoenix Molecular Designs (CA) | 2021-07-14 | — | — | EP | disclosed |
| US-20210186961-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | PHOENIX MOLECULAR DESIGNS (CA) | 2021-06-24 | — | — | US | disclosed |
| EP-3416964-B1 | 6-OXO-N-(1-(BENZYL)-1H-PYRAZOL-4-YL)-6,7,8,9- TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[1,2-A]PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS P90 RIBOSOMAL S6 KINASE (RSK) INHIBITORS FOR TREATING CANCER | PHOENIX MOLECULAR DESIGNS (CA) | 2020-12-16 | — | — | EP | disclosed |
| US-10758530-B2 | Carboxamide derivatives useful as rsk inhibitors | PHOENIX MOLECULAR DESIGNS (CA) | 2020-09-01 | — | — | US | disclosed |
| US-20190134029-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | PHOENIX MOLECULAR DESIGNS (CA) | 2019-05-09 | — | — | US | disclosed |
| EP-3416964-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | Phoenix Molecular Designs (CA) | 2018-12-26 | — | — | EP | disclosed |
| US-10081632-B2 | Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-α]pyrazine-2-carboxamides as RSK inhibitors | PHOENIX MOLECULAR DESIGNS (CA) | 2018-09-25 | — | — | US | disclosed |
| US-20170327501-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | PHOENIX MOLECULAR DESIGNS (CA) | 2017-11-16 | — | — | US | disclosed |
| US-9771366-B2 | Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors | PHOENIX MOLECULAR DESIGN (CA) | 2017-09-26 | — | — | US | disclosed |
| WO-2017141116-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | PHOENIX MOLECULAR DESIGNS (CA) | 2017-08-24 | — | — | WO | disclosed |
| US-20170240549-A1 | TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[1,2-a]PYRAZINE-2-CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | PHOENIX MOLECULAR DESIGNS (CA) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190134029-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | RPS6KA5, RPS6KA2, RPS6KA1 | RPS6KA2 2/4885RPS6KA3 4/4885HRH3 2191/4885 |
| US-20170240549-A1 | TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[1,2-a]PYRAZINE-2-CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | RPS6KA5, RPS6KA2, RPS6KA1 | RPS6KA2 2/4885RPS6KA3 4/4885HRH3 2252/4885 |
| US-10081632-B2 | Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-α]pyrazine-2-carboxamides as RSK inhibitors | RPS6KA2, RPS6KA5, RPS6KA1 | RPS6KA2 1/4885RPS6KA3 6/4885HRH3 1839/4885 |
| US-10758530-B2 | Carboxamide derivatives useful as rsk inhibitors | RPS6KA5, RPS6KA2, RPS6KA1 | RPS6KA2 2/4885RPS6KA3 4/4885HRH3 2191/4885 |
| US-20170327501-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | RPS6KA2, RPS6KA5, RPS6KA1 | RPS6KA2 1/4885RPS6KA3 4/4885HRH3 1827/4885 |
| US-20210186961-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | RPS6KA2, RPS6KA5, RPS6KA1 | RPS6KA2 1/4885RPS6KA3 4/4885HRH3 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.